Form 4: GeneDx Holdings Director Reports Equity Transactions, Including RSU Conversion and New Grant

GeneDx Holdings Corp. Director Richard C. Pfenniger Jr. reported the conversion of 12,924 restricted stock units into Class A Common Stock and the acquisition of 3,576 new restricted stock units.

Summary

• Richard C. Pfenniger Jr., a Director of GeneDx Holdings Corp. (WGS), filed a Form 4 reporting recent equity transactions.
• On June 18, 2025, Mr. Pfenniger acquired 12,924 shares of Class A Common Stock through the exercise/conversion of derivative securities (Restricted Stock Units) at a price of $0.
• Following this transaction, Mr. Pfenniger directly beneficially owns 41,506 shares of Class A Common Stock.
• Additionally, on June 18, 2025, Mr. Pfenniger was granted 3,576 new Restricted Stock Units (RSUs) at a price of $0.
• Each RSU represents a contingent right to receive one share of Class A Common Stock upon settlement for no consideration.
• These new RSUs will vest the earlier of the next annual meeting of shareholders following the grant date or the first anniversary of the grant date, subject to continued service.
• The filing also indicates that 12,924 previously held RSUs were disposed of (converted) as part of the transaction.

Sentiment

Score: 6

Explanation: The filing is a routine insider transaction report. The acquisition of shares through RSU conversion and the grant of new RSUs to a director are generally positive as they indicate continued equity ownership and alignment of interests, but it's not a major market-moving event.

Positives

• Director Richard C. Pfenniger Jr. continues to hold a significant equity stake in GeneDx Holdings Corp., with 41,506 shares of Class A Common Stock beneficially owned directly.
• The grant of 3,576 new Restricted Stock Units (RSUs) to a director indicates ongoing alignment of management incentives with shareholder interests.

Future Outlook

The vesting schedule for the newly granted Restricted Stock Units (RSUs) indicates that they will vest the earlier of the next annual meeting of the Issuer's shareholders following the grant date or the first anniversary of the grant date, contingent on the Reporting Person's continued service to the Issuer.

Industry Context

This Form 4 filing is a routine disclosure of insider equity transactions, common across all publicly traded companies. It reflects a director's compensation structure and ongoing equity ownership, which is a standard practice in the biotechnology and healthcare industry to align executive interests with company performance.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) as part of director compensation is a common practice across publicly traded companies, including those in the biotechnology and genomics sectors.
• The vesting schedule tied to continued service and future events (annual meeting/anniversary) is standard for such equity awards, aiming to retain key personnel and align their long-term interests with shareholder value.
• Specific comparable companies or projects are not detailed in this filing, as it focuses solely on an individual's transaction.

Stakeholder Impact

• Shareholders: The transactions reflect a director's continued equity stake, potentially aligning their interests with shareholder value.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Next Steps

• The newly granted Restricted Stock Units (RSUs) are expected to vest on the earlier of the next annual meeting of GeneDx Holdings Corp. shareholders following the grant date or the first anniversary of the grant date, subject to the director's continued service.

Key Dates

Keywords

GeneDx Holdings Corp., WGS, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Class A Common Stock, Director, Equity Compensation, Stock Grant